Febuxostat Tablets, available in 40 mg and 80 mg strengths from Kureasia Pharma, are advanced urate-lowering agents designed to effectively control hyperuricemia in patients with gout. Gout is a chronic metabolic disorder characterized by elevated uric acid levels, leading to painful inflammation, joint damage, and urate crystal deposits. Febuxostat, a potent and highly selective xanthine oxidase inhibitor, acts by reducing the production of uric acid, thereby helping prevent recurrent gout attacks, joint destruction, and renal complications. Kureasia Pharma’s Febuxostat Tablets are manufactured with precision, ensuring therapeutic efficacy, superior quality, and patient compliance.
Pharmacological Profile:
Febuxostat works through selective inhibition of xanthine oxidase, the key enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid in purine metabolism. By specifically targeting this enzyme, Febuxostat effectively reduces serum uric acid levels without significantly interfering with other enzymes involved in nucleic acid synthesis or energy metabolism. Its selective mechanism makes it more potent and safer than traditional uric acid–lowering agents like allopurinol, particularly in patients who are intolerant or unresponsive to standard therapy.
Therapeutic Indications:
Management of chronic hyperuricemia in adult patients with gout.
Prevention of gout flares and long-term complications associated with urate crystal deposition.
Alternative therapy for patients who cannot tolerate or are inadequately controlled with allopurinol.
Dosage and Administration:
Initial Dose: 40 mg once daily.
Maintenance Dose: If serum uric acid levels remain above 6 mg/dL after two weeks, increase to 80 mg once daily.
Febuxostat can be taken with or without food, allowing flexibility and convenience for patients. Adequate fluid intake should be maintained during therapy to support kidney function and facilitate uric acid excretion.
Mechanism of Action:
By inhibiting xanthine oxidase, Febuxostat decreases uric acid synthesis at its source. This leads to a consistent and sustained reduction of serum uric acid levels, helping prevent urate crystal formation and deposition in joints and tissues. Over time, this contributes to the dissolution of tophi, reduction in inflammation, and improvement in joint mobility and quality of life.
Clinical Benefits:
Provides rapid and sustained reduction in serum uric acid levels.
Offers greater selectivity for xanthine oxidase inhibition compared to allopurinol.
Effective in patients with mild to moderate renal impairment.
Reduces the frequency and severity of gout flares with long-term use.
Enhances patient comfort and quality of life through consistent control of hyperuricemia.
Safety Information and Precautions:
Febuxostat is generally well-tolerated when used as directed. However, patients with severe hepatic impairment or cardiovascular disorders should use it with caution. Periodic monitoring of liver function and serum uric acid levels is recommended during treatment. Febuxostat is not indicated for asymptomatic hyperuricemia and should not be used in patients with known hypersensitivity to the active substance or any of its excipients.
Possible Adverse Effects:
The most commonly observed side effects may include mild skin rashes, nausea, headache, diarrhea, or liver enzyme elevations. Serious hypersensitivity reactions are rare. Patients should seek medical advice if they experience signs of allergic reactions or severe side effects.
Drug Interactions:
Caution should be exercised when Febuxostat is administered with medications such as azathioprine, mercaptopurine, or theophylline, as these drugs are metabolized by xanthine oxidase and may require dose adjustment or monitoring.
Storage and Handling:
Store below 25°C in a cool, dry place. Protect from moisture, direct sunlight, and heat. Keep out of reach of children.
Packaging and Presentation:
Febuxostat Tablets are available in 40 mg and 80 mg strengths, packed in high-quality blister packaging to ensure stability and protection from environmental factors throughout the product’s shelf life.
Manufacturing Excellence – Kureasia Pharma:
At Kureasia Pharma, every product is the result of a commitment to excellence, innovation, and patient well-being. The company adheres to stringent Good Manufacturing Practices (GMP) and global quality standards to ensure the highest level of purity, safety, and efficacy. Kureasia Pharma’s R&D team continuously works on developing advanced formulations to enhance patient outcomes and provide affordable therapeutic options across a broad spectrum of diseases.
Driven by the mission to make quality healthcare accessible globally, Kureasia Pharma consistently invests in technology, infrastructure, and human expertise. The company’s wide range of pharmaceutical products stands as a testament to its dedication to scientific innovation, therapeutic reliability, and ethical healthcare delivery.
Conclusion:
Kureasia Pharma’s Febuxostat Tablets 40 mg and 80 mg are trusted solutions for the effective long-term management of hyperuricemia and gout. Combining scientific precision, clinical efficacy, and uncompromising quality, these tablets offer patients reliable control over uric acid levels, reducing the burden of gout and improving daily comfort and mobility